Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: An analysis of 3691 cases

Blood

Volumn 121, Issue 24, 2013, Pages 4861-4866

  Costa, Luciano J ^a   Xavier, Ana C ^a   Wahlquist, Amy E ^a   Hill, Elizabeth G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BLACK PERSON; BURKITT LYMPHOMA; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SURVIVAL RATE; UNITED STATES; AGE; AGED; CHILD; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; FACTUAL DATABASE; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

MLCS; MLOWN;

EID: 84881305419     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-475558     Document Type: Article

References (25)

1. Mead GM, Barrans SL, Qian W, et al UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112(6):2248-2260.
2. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17(8):2461-2470. (Pubitemid 29368246)
3. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14(3):925-934. (Pubitemid 26085538)
4. Patte C, Auperin A, Michon J, et al; Société Française d'Oncologie Pédiatrique. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370-3379.
5. Gerrard M, Cairo MS, Weston C, et al; FAB LMB96 International Study Committee. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141(6):840-847. (Pubitemid 351724873)
6. Todeschini G, Bonifacio M, Tecchio C, et al. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. Am J Hematol. 2012;87(1):22-25.
7. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569-1580.
8. Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. Br J Haematol. 2012;156(2):234-244.
9. Ribrag V, Koscielny S, Bouabdallah K, et al. Addition of rituximab improves outcome of HIV negative patients with Burkitt lymphoma treated with the Lmba protocol: results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 protocol. (IGR sponsored LMBA02, NCT00180882). ASH Annual Meeting Abstracts. 2012;120:685.
10. Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011;22(8):1859-1864.
11. Shiels MS, Pfeiffer RM, Hall HI, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA. 2011;305(14):1450-1459.
12. Surveillance Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2010 Sub (1973-2008) 〈Katrina/Rita Population Adjustment〉 - Linked To County Attributes - Total U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission.
13. Surveillance Epidemiology, and End Results (SEER) (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2010 Sub (1973-2008 varying) - Linked To County Attributes - Total U.S., 1969-2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission.
14. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York: Springer; 2003.
15. Evens AM, Islam N, Carson KR, et al. A phase 2 clinical trial adding rituximab to CODOX-M/IVAC for untreated Burkitts lymphoma: correlative analysis of serum and CSF rituximab levels. ASH Annual Meeting Abstracts. 2012;120:1640.
16. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOXM/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003;98(6):1196-1205. (Pubitemid 37099904)
17. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248-1254.
18. Burke ME, Albritton K, Marina N. Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer. 2007;110(11):2385-2393. (Pubitemid 350174923)
19. Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC. Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis. Ann Oncol. 2012;23(8):2128-2137.
20. Pollock BH, DeBaun MR, Camitta BM, et al. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol. 2000;18(4):813-823. (Pubitemid 30106612)
21. Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood. 2010;116(20):e90-e98.
22. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117(19):5019-5032.
23. Guech-Ongey M, Simard EP, Anderson WF, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood. 2010;116(25):5600-5604.
24. Rodrigo JA, Hicks LK, Cheung MC, et al. HIV-associated Burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M/IVAC with or without rituximab in the HAART era. Adv Hematol. 2012;2012:735392.
25. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008;113(1):117-125. (Pubitemid 351976392)